Skip to main content
SpringerLink
Log in

Evidence-Based Medicine: What does it Mean and Where Are We Going?

  • Chapter
  • First Online:
Evidence-Based Practice: Toward Optimizing Clinical Outcomes

  • 2438 Accesses

Abstract

Evidence-based medicine (EBM) is commonly defined as “the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients.” However, EBM, which focuses on individual physicians and their decisions, is too limited and should be expanded to include a set of principles and methods intended to ensure that, to the greatest extent possible, medical decisions, guidelines, and other types of policies are based on and consistent with good evidence of efficacy and benefit. There are different methods in which evidence can be used to help in the decision-making process, but a unified approach should be introduced.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. N Engl J Med 350:2343–2351

    Article  PubMed  Google Scholar 

  2. Andrè T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:1–8

    Article  Google Scholar 

  3. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW Jr, Zaza S, GRADE Working Group (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490

    Article  PubMed  Google Scholar 

  4. Austoker J (2001) The potential and pitfalls for developing guidelines in oncology. Ann Oncol 12:1189–1190

    Article  PubMed  CAS  Google Scholar 

  5. Aydiner A, Tas F (2008) Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer. Trials 9:47

    Article  PubMed  Google Scholar 

  6. Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA (2005) Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 97:219–225

    Article  PubMed  Google Scholar 

  7. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027

    Article  PubMed  CAS  Google Scholar 

  8. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419

    Article  PubMed  Google Scholar 

  9. Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG (2005) Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 23:8706–8712

    Article  PubMed  Google Scholar 

  10. Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17:vii10–vii14

    Article  PubMed  Google Scholar 

  11. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J. Clin Oncol 27:663–671

    Article  CAS  Google Scholar 

  12. Brouwers MC, Somerfield MR, Browman GP (2008) A for effort: learning from the application of the GRADE approach to cancer guideline development. J Clin Oncol 26:1033–1039

    Article  Google Scholar 

  13. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228–233

    Article  PubMed  CAS  Google Scholar 

  14. Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD, International Breast Cancer Study Group (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 24:1332–1341

    Article  PubMed  CAS  Google Scholar 

  15. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C, Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1089

    Article  PubMed  CAS  Google Scholar 

  16. Courtè-Wienecke S, Engelbrecht R, v Eimeren W (1999) A survey on the current state of development, dissemination and implementation of guidelines of clinical practice in European countries. Report conducted in the text of the Telematics Application programme for Health Care in the European Union. Medis Institute of Medical Informatics and Health Services Research, Neuherberg

    Google Scholar 

  17. Crivellari D, Aapro M, Leonard R, von Minckwitz G, Brain E, Goldhirsch A, Veronesi A, Muss H (2007) Breast cancer in the elderly. J Clin Oncol 25:1882–1890

    Article  PubMed  Google Scholar 

  18. Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26:1972–1979

    Article  PubMed  CAS  Google Scholar 

  19. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  PubMed  CAS  Google Scholar 

  20. Cuppone F, Bria E, Carlini P, Milella M, Felici A, Sperduti I, Nisticò C, Terzoli E, Cognetti F, Giannarelli D (2008) Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer 113:238–246

    Article  PubMed  CAS  Google Scholar 

  21. De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53

    Article  PubMed  Google Scholar 

  22. De Palma R, Liberati A, Ciccone G, Bandieri E, Belfiglio M, Ceccarelli M, Leoni M, Longo G, Magrini N, Marangolo M, Roila F, Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group (2008) Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricercae Innovazione Emilia Romagna Oncology Research Group. J Clin Oncol 26:1033–1039

    Article  PubMed  Google Scholar 

  23. Deguara C, Dozier N (2007) Evidence-based medicine: setting the standard for high quality patient care. US Oncol (2)

    Google Scholar 

  24. Djulbegovic B, Lyman G, Ruckdeschel JC (2000) Why evidence-based oncology? Evid Based Oncol I:2–5

    Article  Google Scholar 

  25. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  Google Scholar 

  26. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Bowman M (2004) Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 17:59–67

    Article  PubMed  Google Scholar 

  27. Eddy DM (2005) Evidence–based medicine: a unified approach. Health Aff 24:9–17

    Article  Google Scholar 

  28. Evidence-Based Medicine Working Group (1992) Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 268:2420–2425

    Article  Google Scholar 

  29. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK (2009) Taxanes for adjuvant treatment of early breast cancer (Review). Cochrane Database Syst Rev (2)

    Google Scholar 

  30. Fervers B, Burgers JS, Haugh MC, Brouwers M, Browman G, Cluzeau F, Philip T (2005) Predictors of high quality clinical practice guidelines: examples in oncology. Int J Qual Health Care 17:123–132

    Article  PubMed  Google Scholar 

  31. Field MJ, Lohr KN (1990) Clinical practice guidelines. Institute of Medicine, National Academy, Washington, DC

    Google Scholar 

  32. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690

    Article  PubMed  CAS  Google Scholar 

  33. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673–1682

    Article  PubMed  CAS  Google Scholar 

  34. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N (2004) National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858–868

    Article  PubMed  CAS  Google Scholar 

  35. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG (1990) Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005–1018

    PubMed  CAS  Google Scholar 

  36. Fleisher LA, Bass EB, McKeown P (2005) Methodological approach: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 128:17S–23S

    Article  PubMed  Google Scholar 

  37. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M, Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53

    Article  PubMed  Google Scholar 

  38. Gill S, Loprinzi C, Sargent D, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806

    Article  PubMed  CAS  Google Scholar 

  39. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ (2007) 10th St. Gallen conference Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol 18:1917

    Article  Google Scholar 

  40. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271

    Article  PubMed  CAS  Google Scholar 

  41. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D (2008) Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26:1948–1955

    Article  PubMed  CAS  Google Scholar 

  42. Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M (2008) Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer 8:411–417

    Article  PubMed  CAS  Google Scholar 

  43. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schünemann HJ, GRADE Working Group (2008) Going from evidence to recommendations. BMJ 336:1049–1051

    Article  PubMed  Google Scholar 

  44. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, GRADE Working Group (2008) What is “quality of evidence” and why is it important to clinicians? BMJ 336:995–998

    Article  PubMed  Google Scholar 

  45. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ (1995) Users guides to the medical literature. IX. A method for grading health care recommendations. JAMA 274:1880–1884

    Article  Google Scholar 

  46. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D, Methods Work Group, Third US Preventive Services Task Force (2001) Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20:21–35

    Article  PubMed  CAS  Google Scholar 

  47. Hase K, Ueno H, Kuranaga N, Utsunomiya K, Kanabe S, Mochizuki H (1998) Intraperitoneal exfoliated cancer cells in patients with colorectal cancer. Dis Colon Rectum 41:1134–1140

    Article  PubMed  CAS  Google Scholar 

  48. Haynes RB (2006) Of studies, syntheses, synopses, summaries, and systems: the “5S” evolution of information services for evidence-based health care decisions. Evid Based Med 11:162–164

    Article  PubMed  Google Scholar 

  49. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672–680

    Article  PubMed  CAS  Google Scholar 

  50. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605–613

    Article  PubMed  CAS  Google Scholar 

  51. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  52. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J, ABCSG and the GABG (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462

    Article  PubMed  CAS  Google Scholar 

  53. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators (2006) Adjuvant docetaxel or vinorelvine with or without trastuzumab for breast cancer. N Engl J Med 23:809–820

    Article  Google Scholar 

  54. Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177–1183

    Article  PubMed  CAS  Google Scholar 

  55. Kabbinavar F, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706–3712

    Article  PubMed  CAS  Google Scholar 

  56. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65

    Article  PubMed  CAS  Google Scholar 

  57. Kabbinavar F, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J Clin Oncol 23:3697–3705

    Article  PubMed  CAS  Google Scholar 

  58. Kruer MC, Steiner RD (2008) The role of evidence-based medicine and clinical trials in rare genetics disorders. Clin Genet 74:197–207

    Article  PubMed  CAS  Google Scholar 

  59. Kuebler JP, Wieand HS, O’Connel MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204

    Article  PubMed  CAS  Google Scholar 

  60. Mieog JS, van der Hage JA, van de Velde CJ (2007) Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94:1189–1200

    Article  PubMed  CAS  Google Scholar 

  61. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

    Article  PubMed  CAS  Google Scholar 

  62. Nathanson SD (1994) Is there a role for clinical prognostic factors in staging patients with colorectal cancer? Semin Surg Oncol 10:176–182

    Article  PubMed  CAS  Google Scholar 

  63. NIH consensus conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444–1450

    Article  Google Scholar 

  64. O’Connell MJ (2009) Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol 27:1–3

    Article  Google Scholar 

  65. Pentheroudakis G, Stahel R, Hansen H, Pavlidis N (2008) Heterogeneity in cancer guidelines: should we eradicate or tolerate? Ann Oncol 19:2067–2078

    Article  PubMed  CAS  Google Scholar 

  66. Philip T, Fervers B, Haugh M, Otter R, Browman G (2003) European cooperation for clinical practice guidelines in cancer. Br J Cancer 89:SI–S3

    Article  Google Scholar 

  67. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapyin HER2-positive breast cancer. N Engl J Med 20:1659–1672

    Article  Google Scholar 

  68. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778–785

    Article  PubMed  Google Scholar 

  69. Ray-Coquard I, Philip T, Lehmann M, Fervers B, Farsi F, Chauvin F (1997) Impact of a clinical guidelines program for breast and colon cancer in a French cancer center. JAMA 278:1591–1595

    Article  PubMed  CAS  Google Scholar 

  70. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab chemotherapy for operable HER2-positive breast cancer. N Engl J Med 20:1673–1684

    Article  Google Scholar 

  71. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women’s health initiative randomized controlled trial. JAMA 288:321–333

    Article  PubMed  CAS  Google Scholar 

  72. Rubenstein JH, Inadomi JM (2006) Evidence based medicine (EBM) in practice: applying results of cost-effectiveness analyses. Am J Gastroenerol 6:1169–1171

    Article  Google Scholar 

  73. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. BMJ 312:71–72

    Article  PubMed  CAS  Google Scholar 

  74. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208

    Article  PubMed  CAS  Google Scholar 

  75. Sant M, Capocaccia R, Coleman MP, Berrino F, Gatta G, Micheli A, Verdecchia A, Faivre J, Hakulinen T, Coebergh JW, Martinez-Garcia C, Forman D, Zappone A (2001) EUROCARE Working Group Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 37:1659–1667

    Article  PubMed  CAS  Google Scholar 

  76. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097

    Article  PubMed  CAS  Google Scholar 

  77. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C, X-ACT Study Group (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14:1735–1743

    Article  PubMed  CAS  Google Scholar 

  78. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, Chan A, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, Mackey J, Tabah-Fisch I, Buyse M, Lindsay M, Riva A, Bee V, Pegram M, Press M, Crown J (2006) BCIRG 006: 2nd interim analysis Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC>T) with docetaxel, carboplatin and trastuzumab (TCH) in HER2/neu positive early breast cancer patients. Breast Cancer Res Treat 106:52a

    Google Scholar 

  79. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  80. Spielmann M, Roché H, Humblet Y, Delozier T, Bourgeois H, Serin D, Romieu G, Canon JL, Monnier A, Piot G, Maerevoet M, Orfeuvre H, Extra JM, Hardy AC, Martin AL, Kramar A, Geneve J (2007) 3-year follow-up of trastuzumab following adjuvant chemotherapy in node-positive HER2-positive breast cancer patients: results of the PACS-04 trial. Breast Cancer Res Treat 106:S72

    Google Scholar 

  81. Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, Prescott RJ, George WD (1996) Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 74:297–299

    Article  PubMed  CAS  Google Scholar 

  82. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879

    Article  PubMed  CAS  Google Scholar 

  83. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ (2008) A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colrorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19:734–738

    Article  PubMed  CAS  Google Scholar 

  84. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–2704

    Article  PubMed  CAS  Google Scholar 

  85. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J, Köhne C (2007) Randomized Phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25:18S

    Google Scholar 

  86. van Cutsem EJ, Oliveira J (2008) Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 19:ii29–ii30

    Article  PubMed  Google Scholar 

  87. Wolff CA, Desch CE (2005) Clinical practice guidelines in oncology: translating evidence in to practice (and back). J Oncol Pract 4:160–161

    Article  Google Scholar 

  88. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96–102

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Via F. Gallini, 2, Aviano, Italy

    Sergio Frustaci, Gian Maria Miolo & Angela Buonadonna

  2. Division of Medical Oncology C, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Via F. Gallini, 2, Aviano, Italy

    Diana Crivellari & Simona Scalone

Authors
  1. Sergio Frustaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gian Maria Miolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Buonadonna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Diana Crivellari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Simona Scalone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergio Frustaci .

Editor information

Editors and Affiliations

  1. School of Dentistry, Div. Oral Biology & Medicine, University of California, Los Angeles, Los Angeles, 90095-1668, USA

    Francesco Chiappelli

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Frustaci, S., Miolo, G.M., Buonadonna, A., Crivellari, D., Scalone, S. (2010). Evidence-Based Medicine: What does it Mean and Where Are We Going?. In: Chiappelli, F. (eds) Evidence-Based Practice: Toward Optimizing Clinical Outcomes. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-05025-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-05025-1_14

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-05024-4

  • Online ISBN: 978-3-642-05025-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation